PT  - JOURNAL ARTICLE
AU  - TORU BEPPU
AU  - YASUNORI EMI
AU  - SHOJI TOKUNAGA
AU  - EIJI OKI
AU  - KEN SHIRABE
AU  - SHINICHI UENO
AU  - MASAFUMI KURAMOTO
AU  - AKIRA KABASHIMA
AU  - IKUO TAKAHASHI
AU  - HIRONORI SAMURA
AU  - SUSUMU EGUCHI
AU  - YOSHITO AKAGI
AU  - SHOJI NATSUGOE
AU  - YUTAKA OGATA
AU  - YOSHIHIRO KAKEJI
AU  - HIDEO BABA
AU  - YOSHIHIKO MAEHARA
AU  - KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)
TI  - Liver Resectability of Advanced Liver-limited Colorectal Liver Metastases Following mFOLFOX6 with Bevacizumab (KSCC0802 Study)
DP  - 2014 Nov 01
TA  - Anticancer Research
PG  - 6655--6662
VI  - 34
IP  - 11
4099  - http://ar.iiarjournals.org/content/34/11/6655.short
4100  - http://ar.iiarjournals.org/content/34/11/6655.full
SO  - Anticancer Res2014 Nov 01; 34
AB  - Background/Aim: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802 - UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. Patients and Methods: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. Results: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. Conclusion: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability.